• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 11:16:57 AM ET
    $LOGC
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $LOGC alert in real time by email
    SC 13G/A 1 ea135739-13ga2ran_logicbio.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 2)

     

    (Rule 13d-102)

     

    Under the Securities Exchange Act of 1934

     

    LogicBio Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    54142F102

    (CUSIP Number)

     

    February 7, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)

     

      ☐ Rule 13d-1(c)

     

      ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 54142F102 13G Page 2 of 10 Pages

     

    1.

    Names of Reporting Persons

     

    Ran Nussbaum

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (c) ☐

    (d) ☐

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,499,0531

    7.

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    1,499,0531

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,499,0531

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    4.7%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

     

      1. Consists of: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P.

     

    Pontifax 4 G.P., Limited Partnership is the general partner of Pontifax (Israel) IV, Limited Partnership, Pontifax (Cayman) IV, L.P. and Pontifax (China) IV, L.P. Pontifax Management IV, G.P. (2015) Ltd. is the general partner of Pontifax 4 G.P., Limited Partnership. Ran Nussbaum and Tomer Kariv are directors of Pontifax IV, G.P. (2015) Ltd. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

     

     

     

    CUSIP No. 54142F102 13G Page 3 of 10 Pages

     

    1.

     

    Names of Reporting Persons

     

    Tomer Kariv

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (e) ☐

    (f) ☐

     

    3.

    SEC Use Only

     

    4.

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

     

     

    Sole Voting Power

     

    8,0331

    6.

     

     

    Shared Voting Power

     

    1,499,0532

    7.

     

     

    Sole Dispositive Power

     

    8,0331

    8.

     

     

    Shared Dispositive Power

     

    1,499,0532

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,507,0873

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    4.7%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    IN

     

    1. Consists of options to purchase 8,033 ordinary shares exercisable within 60 days of December 31, 2020.

     

    2. Consists of: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P.

     

    3. See notes 1 and 2 above.

     

    Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

     

     

     

    CUSIP No. 54142F102 13G Page 4 of 10 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Pontifax 4 G.P., Limited Partnership

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (g) ☐

    (h) ☐

     

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,499,0531

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    1,499,0531

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,499,0531

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    4.7%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    PN

     

    1. Consists of: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

     

     

     

    CUSIP No. 54142F102 13G Page 5 of 10 Pages

     

    1.

     

     

    Names of Reporting Persons

     

    Pontifax Management IV, G.P. (2015) Ltd.

    2.

     

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (i) ☐

    (j) ☐

     

    3.

    SEC Use Only

     

    4.

     

     

    Citizenship or Place of Organization

     

    Israel

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    1,499,0531

    7.

    Sole Dispositive Power

     

    0 

    8.

    Shared Dispositive Power

     

    1,499,0531

    9.

     

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,499,0531

    10.

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ☐ 

    11.

     

     

    Percent of Class Represented by Amount in Row (9)

     

    4.7%

    12.

     

     

    Type of Reporting Person (See Instructions)

     

    CO

     

    1. Consists of: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

     

     

     

    CUSIP No. 54142F102 13G Page 6 of 10 Pages

     

    Introductory Note: This Schedule 13G is filed on behalf of Pontifax 4 G.P., Limited Partnership, a limited partnership organized under the laws of the State of Israel, Pontifax Management IV, G.P. (2015) Ltd., an Israeli company, Ran Nussbaum and Tomer Kariv (the “Reporting Persons”), in respect of shares of common stock of LogicBio Therapeutics, Inc.

     

    Item 1(a). Name of Issuer:

     

    LogicBio Therapeutics, Inc. 

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

     

    65 Hayden Avenue, 2nd Floor, Lexington, MA 02421

     

    Item 2(a). Name of Person Filing:

     

    This Statement is filed on behalf of Pontifax 4 G.P., Limited Partnership, Pontifax Management IV, G.P. (2015) Ltd., Ran Nussbaum. and Tomer Kariv.

     

    Item 2(b). Address of Principal Offices or, if None, Residence:

     

    The addresses of the Reporting Persons are:

     

    Pontifax 4 G.P., Limited Partnership - 14 Shenkar St. Herzliya, 46140, Israel

     

    Pontifax Management IV, G.P. (2015) Ltd. – 14 Shenkar St. Herzliya, 46140, Israel

     

    Ran Nussbaum - 14 Shenkar St. Herzliya, 46140, Israel

     

    Tomer Kariv - 14 Shenkar St. Herzliya, 46140, Israel

     

    Item 2(c). Citizenship:

     

    Pontifax 4 G.P., Limited Partnership is organized in the State of Israel, Pontifax Management IV, G.P. (2015) Ltd. is incorporated in the State of Israel, Ran Nussbaum is a citizen of the State of Israel, and Tomer Kariv is a citizen of the State of Israel.

     

    Item 2(d). Title of Class of Securities:

     

    Shares of common stock

     

    Item 2(e). CUSIP Number:

     

    54142F102

     

     

     

    CUSIP No. 54142F102 13G Page 7 of 10 Pages

     

    Item 3. If the Statement is being filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the filing person is a:

     

    Not applicable.

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

     

      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                                                           

      

    Item 4. Ownership.

     

      (a) Amount beneficially owned:

     

    Tomer Kariv: 1,507,087 shares1

    Other Reporting Persons: 1,499,053 shares

     

      (b) Percent of class:

     

    4.7%1

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or direct the vote:

     

    Tomer Kariv – 8,033 shares

     

     

     

    CUSIP No. 54142F102 13G Page 8 of 10 Pages

     

      (ii) Shared power to vote or direct the vote: 1,499,053 shares1

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    Tomer Kariv – 8,033 shares

     

      (iv) Shared power to dispose or to direct the disposition of: 1,499,053 shares1

     

    1. Includes: (i) 739,466 shares of common stock owned by Pontifax (Israel) IV, Limited Partnership, (ii) 360,594 shares of common stock owned by Pontifax (Cayman) IV, L.P., and (iii) 398,993 shares of common stock owned by Pontifax (China) IV, L.P. In addition, for Mr. Kariv, includes options to purchase 8,033 ordinary shares exercisable within 60 days of December 31, 2020.

     

    Pontifax 4 G.P., Limited Partnership is the general partner of Pontifax (Israel) IV, Limited Partnership, Pontifax (Cayman) IV, L.P. and Pontifax (China) IV, L.P. Pontifax Management IV, G.P. (2015) Ltd. is the general partner of Pontifax 4 G.P., Limited Partnership. Ran Nussbaum and Tomer Kariv are directors of Pontifax IV, G.P. (2015) Ltd. Each of Ran Nussbaum and Tomer Kariv disclaim beneficial ownership of the shares reported in this Schedule 13G, as amended, and the inclusion of such shares in this Schedule 13G shall not be deemed to be an admission of beneficial ownership of the reported shares.

      

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person had ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    Not applicable.

     

     

     

    CUSIP No. 54142F102 13G Page 9 of 10 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2021
         
    PONTIFAX 4 G.P., LIMITED PARTNERSHIP  
         
    By: /s/ Pontifax Management IV G.P. (2015) Ltd.  
    Name:  Pontifax Management IV G.P. (2015) Ltd.  
    Title: General Partner  
         
    By: /s/ Ran Nussbaum  
    Name: Ran Nussbaum  
    Title: Director  
         
    PONTIFAX MANAGEMENT IV, G.P. (2015) LTD.  
         
    By: /s/ Ran Nussbaum  
    Name: Ran Nussbaum  
    Title: Director  
         
    /s/ Tomer Kariv  
    TOMER KARIV  

     

    /s/ Ran Nussbaum  
    Ran Nussbaum  

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

    CUSIP No. 54142F102 13G Page 10 of 10 Pages

     

    EXHIBIT INDEX

     

    A. Joint Filing Agreement, dated as of February 14, 2020, by and among Pontifax 4 G.P., Limited Partnership, Pontifax Management IV, G.P. (2015) Ltd., Ran Nussbaum and Tomer Kariv. (Incorporated by reference from the Schedule 13G filed by the Reporting Persons with respect to the Issuer on February 14, 2020).

      

     

     

     

     

    Get the next $LOGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LOGC

    DatePrice TargetRatingAnalyst
    2/3/2022Outperform → Market Perform
    William Blair
    2/2/2022$16.00 → $6.00Hold
    Chardan Capital
    12/23/2021$20.00 → $16.00Buy
    Chardan Capital
    11/17/2021$24.00 → $8.00Overweight
    Barclays
    11/16/2021$17.00 → $16.00Market Outperform
    JMP Securities
    More analyst ratings

    $LOGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bajaj Rishi converted options into 55,856 shares and covered exercise/tax liability with 24,722 shares, increasing direct ownership by 156% to 51,134 units (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      5/8/25 4:10:12 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Heinberg Marshall converted options into 25,684 shares (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      4/21/25 8:44:49 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Director Farlekas Michael converted options into 25,684 shares (SEC Form 4)

      4 - ContextLogic Inc. (0001822250) (Issuer)

      4/21/25 8:44:13 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ContextLogic Inc. Reports First-Quarter 2025 Financial Results

      OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a

      5/9/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic to Announce First Quarter 2025 Results on May 9, 2025

      OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering

      5/6/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

      OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along

      3/12/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LogicBio Therapeutics downgraded by William Blair

      William Blair downgraded LogicBio Therapeutics from Outperform to Market Perform

      2/3/22 4:38:49 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Chardan Capital reiterated coverage on LogicBio Therapeutics with a new price target

      Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Hold and set a new price target of $6.00 from $16.00 previously

      2/2/22 2:52:41 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Chardan Capital reiterated coverage on LogicBio Therapeutics with a new price target

      Chardan Capital reiterated coverage of LogicBio Therapeutics with a rating of Buy and set a new price target of $16.00 from $20.00 previously

      12/23/21 8:24:38 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ContextLogic Inc.

      SC 13G/A - ContextLogic Inc. (0001822250) (Subject)

      7/8/24 4:32:41 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • SEC Form SC 13G/A filed by LogicBio Therapeutics Inc. (Amendment)

      SC 13G/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)

      2/14/23 1:47:10 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • SEC Form SC 13D/A filed by LogicBio Therapeutics Inc. (Amendment)

      SC 13D/A - LogicBio Therapeutics, Inc. (0001664106) (Subject)

      2/10/23 4:40:05 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    SEC Filings

    See more
    • SEC Form 10-Q filed by ContextLogic Inc.

      10-Q - ContextLogic Inc. (0001822250) (Filer)

      5/9/25 4:30:19 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ContextLogic Inc. (0001822250) (Filer)

      5/9/25 4:05:15 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • Amendment: SEC Form SCHEDULE 13G/A filed by ContextLogic Inc.

      SCHEDULE 13G/A - ContextLogic Inc. (0001822250) (Subject)

      4/18/25 3:58:12 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Financials

    Live finance-specific insights

    See more
    • ContextLogic Inc. Reports First-Quarter 2025 Financial Results

      OAKLAND, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter ended March 31, 2025. First-Quarter 2025 Financial Highlights Net Loss: Net loss was $4 million, compared to a net loss of $59 million in the first quarter of fiscal year 2024.As of March 31, 2025, the Company had $64 million in cash and cash equivalents, $158 million in marketable securities and $1 million in prepaid expenses and other current assets primarily made up of restricted cash. The Company had total liabilities of $3 million. ContextLogic will host a financial results conference call a

      5/9/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic to Announce First Quarter 2025 Results on May 9, 2025

      OAKLAND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") today announced it will report its first quarter 2025 financial results after the close of market on Friday, May 9, 2025. ContextLogic's CEO Rishi Bajaj and its Chairman Ted Goldthorpe will host a live conference call and webcast for shareholders, analysts and portfolio managers that afternoon at 5:00 PM ET / 2:00 PM PT. Information about the Company's financial results, including a link to the live webcast and replay will be made available on the Company's investor relations website at https://ir.contextlogicinc.com. The live conference call may be accessed by registering

      5/6/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • ContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial Results

      OAKLAND, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC) ("ContextLogic," the "Company," "we" or "our") today reported its financial results for the quarter and fiscal year ended December 31, 2024. Company Update During 2024, management took several significant steps in the evolution of the Company's business. These included, first, the sale of the Wish platform and its associated operations; second, streamlining the Company's operations; and most recently, on March 11, 2025, the Company announced the initial closing of the investment by BC Partners of $75 million in convertible preferred units in a subsidiary of ContextLogic. This investment, along

      3/12/25 4:00:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary

    $LOGC
    Leadership Updates

    Live Leadership Updates

    See more
    • ContextLogic Announces Up to $150 Million Strategic Investment by BC Partners

      Strategic investment and capital commitment positions the Company to execute on its stated acquisition-led value maximization strategy; ContextLogic to have up to $300 million of investible cash Ted Goldthorpe, Head of BC Partners Credit, expected to be named Chairman of the Board OAKLAND, Calif. and NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ContextLogic Inc. (NASDAQ:LOGC), ("ContextLogic" or the "Company") and BC Partners, an alternative investment manager with c.€40 billion in assets under management, today announced that a fund advised by BC Partners Advisors L.P. will purchase up to $150 million of convertible preferred units (the "Preferred Units") of ContextLogic Holdings, L

      2/25/25 8:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

      LEXINGTON, Mass., March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company, today reported financial results for the year ended December 31, 2021, and provided business updates. "At LogicBio, we are continuing to advance our mission to safely deliver novel genetic medicines to people impacted by devastating, early onset diseases," said Frederic Chereau, president and chief executive officer of LogicBio. "We are pleased to report that the serious adverse event experienced by the fourth patient enrolled in our Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia has resolved." Recent Business Update

      3/4/22 4:05:00 PM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary
    • LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments

      LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the promotion of Daniel Gruskin, MD, as chief medical officer. Dr. Gruskin most recently served as senior vice president and head of clinical development. The Company also announced the appointment of Stephen Boyer, PhD, as vice president of regulatory and quality affairs, and Peter Pechan, PhD, as vice president of gene therapy, who will support progress in the Phase I/II SUNRISE clinical trial of LB-001, the Company's investi

      5/19/21 7:00:00 AM ET
      $LOGC
      Catalog/Specialty Distribution
      Consumer Discretionary